Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:
NCT00055939
First received: March 6, 2003
Last updated: May 15, 2012
Last verified: May 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2006
  Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)